A patient with systemic lupus erythematosus (SLE) developed amegakaryocytic thrombocytopenic purpura. The absence of a drug relationship or other identifiable underlying cause madeus consider this to be a rare manifestation of SLE. Her thrombocytopenia, which initially appeared to be steroid-resistant, ultimately improved following a prolonged high-dose prednisolone therapy. To our knowledge, this is the second case of amegakaryocytic thrombocytopenia associated with SLEin the literature. The possibility that amegakaryocytic thrombocytopenia in SLE can be caused by cellular rather than humoral immunologic mechanism was discussed.
therapy

Thrombocytopenia
has been reported to occur in 14 to 26% of patients with systemic lupus erythematosus (SLE) . In these patients, a shortened platelet survival time and increased numberof marrowmegakaryocytes are commonly found.
In contrast, thrombocytopenia associated with amegakaryocytic bone marrow is extremely rare in SLE. To our knowledge, only one case of this kind has been reported in the past . The patient, however, failed to respond to treatment.
The present report describes the second case of amegakaryocytic thrombocytopenia associated with SLE successfully treated by a high-dose prednisolone therapy.
REPORT OF A CASE
A 47-year-old house-wife was referred to the Tsukuba University Hospital in November 1981 because of thrombocytopenic purpura. No attempt was made to carry out a platelet survival study with autologous platelets because of severe throbmocytopenia.
The results of 59Fe clearance and 59Fe utilization studies were within the normal limits (Table 1) . PPD skin test was negative. A second bone marrow aspiration again revealed the absence of megakaryocytes. Although the cell count was slightly decreased, erythroid and myeloid cell series were normally matured (Table  1 ). An iliac crest bone marrow biopsy examination provided essentially identical findings (Fig. 2) .
She was maintained on 60 mg of prednisolone but the platelet count remained extremely low. On the 33rd hospital day a pulse therapy (methylprednisolone 1.0 gm I.V. x3) was tried without immediate signs of improvement on the platelet count, and the patient continued to manifest bleeding tendencies.
Further continuation of the high-dose prednisolone was attempted before judging the case to be refractory to steroid therapy, although steroid-induced myopathy was prominent at this point. On the 59th hospital day (the 66th day from the start of 60 mg of prednisolone), the platelet count increased to 2.5 x 104/mm3 followed by an acute rise to 20 x 104/mm3 in 2 weeks (Fig. 1) . Repeated bone marrow aspiration on the 68th hospital day revealed normal bone marrow with many matured megakaryocytes.
Prednisolone was gradually tapered down to 12.5 mg at the rate of 10% every 2 weeks. The platelet levels remained stable within the normal range and she was discharged on the 243rd hospital day.
DISCUSSION
Thrombocytopenia occurring in SLEis usually associated with normal or increased number of megakaryocytes in the bone marrow1. Humoral immunologic abnormalities are thought to be operative in the pathogenesis of thrombocytopenia . As a rule the effect of corticosteroid on platelet levels becomes evident within a few weeks.
Amegakaryocytic thrombocytopenia may be due to a variety of causes. Constitutional anemia (Fanconi syndrome) and familial forms of thrombocytopenia could be excluded in our case. Among acquired forms of amegakaryocytic thrombocytopenia, aplastic anemia, marrowinfiltrative processes and those associated with megaloblastic anemias could be ruled out on clinical and hematologic grounds. Drug-induced amegakaryocytic thrombocytopenia could be a possibility.
Our patient had been exposed to methyldopa and small doses of prednisolone prior to the onset of thrombocytopenia. This hypotensive drug can induce thrombocytopenia but rarely and only 3 cases have been reported in the past6 . In all of these, the results of bone marrow examination have not been described.
However, since platelet number started to increase within a few days after the drug withdrawal, it should be reasonable to assume that megakaryocytes had been present in their bone marrow. We could find, therefore, no precedent for persistent amegakaryocytic thrombocytopenia due to methyldopa. This was considered strong evidence against methyldopa being responsible for thrombocytopenia in our case. 
